The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.

IF 3.4 3区 医学 Q2 CLINICAL NEUROLOGY
CNS Spectrums Pub Date : 2024-12-01 Epub Date: 2024-12-10 DOI:10.1017/S1092852924002268
Mauro Scala, Chiara Fabbri, Paolo Fusar-Poli, Giorgio Di Lorenzo, Maria Ferrara, Andrea Amerio, Laura Fusar-Poli, Anna Pichiecchio, Carlo Asteggiano, Marco Menchetti, Diana De Ronchi, Giuseppe Fanelli, Alessandro Serretti
{"title":"The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.","authors":"Mauro Scala, Chiara Fabbri, Paolo Fusar-Poli, Giorgio Di Lorenzo, Maria Ferrara, Andrea Amerio, Laura Fusar-Poli, Anna Pichiecchio, Carlo Asteggiano, Marco Menchetti, Diana De Ronchi, Giuseppe Fanelli, Alessandro Serretti","doi":"10.1017/S1092852924002268","DOIUrl":null,"url":null,"abstract":"<p><p>The revival of psilocybin in psychopharmacological research heralds a potential paradigm shift for treating mood and anxiety disorders, and other psychiatric conditions beyond the psychotic spectrum. This critical review evaluates current evidence on psilocybin's efficacy, juxtaposing potential benefits with the practical aspects of psychedelic-assisted psychotherapy (PAP) and the methodological constraints of existing research.An electronic literature search was conducted using PubMed/MEDLINE, selecting studies published up to December 2023 that explored the clinical use of psilocybin in mood and anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, and substance use disorder. Despite promising preliminary results suggesting psilocybin's efficacy in alleviating depression and anxiety, as well as obsessions, compulsions, and addictive behaviors, significant evidence gaps persist. These include evaluating the efficacy of psilocybin compared to standard antidepressants or anxiolytic molecules and identifying patient subpopulations that might benefit most from PAP. Concerns about psilocybin's safety, long-term efficacy, and optimal dosage remain unclear due to previous trials' limitations. Real-world implementation faces challenges, including infrastructural requirements, personnel training, and unresolved legal and ethical issues. This paper argues for further research to substantiate the evidence base, emphasizing the need for larger studies that overcome current methodological limitations and explore psilocybin's full therapeutic potential. While psilocybin holds promise for psychiatry, its successful translation from research to clinical practice demands more robust evidence on efficacy, safety, and methodological rigor. In addition, other factors, such as cultural stigma and legal/ethical issues, need to be successfully addressed to facilitate psilocybin's implementation in healthcare systems.</p>","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"570-584"},"PeriodicalIF":3.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Spectrums","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S1092852924002268","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The revival of psilocybin in psychopharmacological research heralds a potential paradigm shift for treating mood and anxiety disorders, and other psychiatric conditions beyond the psychotic spectrum. This critical review evaluates current evidence on psilocybin's efficacy, juxtaposing potential benefits with the practical aspects of psychedelic-assisted psychotherapy (PAP) and the methodological constraints of existing research.An electronic literature search was conducted using PubMed/MEDLINE, selecting studies published up to December 2023 that explored the clinical use of psilocybin in mood and anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, and substance use disorder. Despite promising preliminary results suggesting psilocybin's efficacy in alleviating depression and anxiety, as well as obsessions, compulsions, and addictive behaviors, significant evidence gaps persist. These include evaluating the efficacy of psilocybin compared to standard antidepressants or anxiolytic molecules and identifying patient subpopulations that might benefit most from PAP. Concerns about psilocybin's safety, long-term efficacy, and optimal dosage remain unclear due to previous trials' limitations. Real-world implementation faces challenges, including infrastructural requirements, personnel training, and unresolved legal and ethical issues. This paper argues for further research to substantiate the evidence base, emphasizing the need for larger studies that overcome current methodological limitations and explore psilocybin's full therapeutic potential. While psilocybin holds promise for psychiatry, its successful translation from research to clinical practice demands more robust evidence on efficacy, safety, and methodological rigor. In addition, other factors, such as cultural stigma and legal/ethical issues, need to be successfully addressed to facilitate psilocybin's implementation in healthcare systems.

裸盖菇素在科学兴奋、疗效证据和现实世界挑战之间的复兴。
裸盖菇素在精神药理学研究中的复兴预示着治疗情绪和焦虑障碍以及其他精神病谱系之外的精神疾病的潜在范式转变。这篇重要的综述评估了目前关于裸盖菇素疗效的证据,并将潜在的益处与迷幻辅助心理治疗(PAP)的实际方面和现有研究的方法学限制并列。使用PubMed/MEDLINE进行电子文献检索,选择截至2023年12月发表的研究,探讨裸盖菇素在情绪和焦虑症、强迫症、创伤后应激障碍和物质使用障碍中的临床应用。尽管初步结果表明裸盖菇素在缓解抑郁和焦虑,以及强迫症、强迫症和成瘾行为方面有功效,但显著的证据差距仍然存在。这些包括评估裸盖菇素与标准抗抑郁药或抗焦虑药分子的疗效,并确定可能从PAP中获益最多的患者亚群。由于先前试验的局限性,对裸盖菇素的安全性、长期疗效和最佳剂量的担忧仍不清楚。现实世界的实现面临着挑战,包括基础设施需求、人员培训以及未解决的法律和道德问题。本文认为需要进一步的研究来证实证据基础,强调需要进行更大规模的研究,以克服当前方法的局限性,并探索裸盖菇素的全部治疗潜力。尽管裸盖菇素有望用于精神病学,但其从研究到临床实践的成功转化需要更多关于有效性、安全性和方法严谨性的有力证据。此外,其他因素,如文化污名和法律/伦理问题,需要成功解决,以促进裸盖菇素在医疗保健系统中的实施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CNS Spectrums
CNS Spectrums 医学-精神病学
CiteScore
6.20
自引率
6.10%
发文量
239
审稿时长
>12 weeks
期刊介绍: CNS Spectrums covers all aspects of the clinical neurosciences, neurotherapeutics, and neuropsychopharmacology, particularly those pertinent to the clinician and clinical investigator. The journal features focused, in-depth reviews, perspectives, and original research articles. New therapeutics of all types in psychiatry, mental health, and neurology are emphasized, especially first in man studies, proof of concept studies, and translational basic neuroscience studies. Subject coverage spans the full spectrum of neuropsychiatry, focusing on those crossing traditional boundaries between neurology and psychiatry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信